Payer costs of patients diagnosed with epilepsy.

Payer costs of patients diagnosed with epilepsy.

Pokaż inne wersje (1)

PURPOSE: To identify the annual cost to a third-party payer of inpatient and outpatient services and prescription drugs for patients diagnosed with epilepsy or convulsions. METHODS: Retrospective study using administrative and claims data from a private insurer in the Northeast United States with &a...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy:	Griffiths, R, Schrammel, P, Morris, G, Wills, S, Labiner, D, Strauss, M
Format:	Journal article
Język:	English
Wydane:	Lippincott Williams and Wilkins 1999

Podobne zapisy

Payer costs of patients diagnosed with epilepsy
od: Griffiths, R
Wydane: (1999)

Factors influencing third party payer costs for allogeneic BMT.
od: Griffiths, R, i wsp.
Wydane: (1993)

The global cost of epilepsy: a systematic review and extrapolation
od: Begley, C, i wsp.
Wydane: (2022)

Pourquoi Payer ?
od: Mary Ann Bates, i wsp.
Wydane: (2012-01-01)

A workplace breast cancer screening program. Costs and components.
od: Schrammel, P, i wsp.
Wydane: (1998)

Single-Payer Health Care Reform: Cost Considerations in Maine
od: Daniel Bryant
Wydane: (2024-09-01)

Patient and Payer Preferences for Additional Value Criteria
od: Ivett Jakab, i wsp.
Wydane: (2021-06-01)

Unreliable VAT payer
od: Vladimír Balcar
Wydane: (2021-06-01)

The Payer and Patient Cost Burden of Open Breast Conserving Procedures Following Percutaneous Breast Biopsy
od: Chloe C Kimball, i wsp.
Wydane: (2018-06-01)

Prostate cancer screening in the workplace. Employer costs.
od: Snyder, C, i wsp.
Wydane: (1998)

Impact of payer rejections and out-of-pocket costs on patient access to bempedoic acid therapy
od: Jimin Hwang, i wsp.
Wydane: (2025-03-01)

Are payers treating orphan drugs differently?
od: Joshua P. Cohen, i wsp.
Wydane: (2014-01-01)

Cost of hospitalization for firearm injuries by firearm type, intent, and payer in the United States
od: Corinne Peek-Asa, i wsp.
Wydane: (2017-07-01)

The global economic burden of epilepsy
od: Begley, C, i wsp.
Wydane: (2021)

Costs of Hip Fractures in Postmenopausal Women in Portugal: A Study from the Payer’s Perspective
od: Anabela Barcelos, i wsp.
Wydane: (2023-12-01)

Cost–effectiveness of overactive bladder treatments from a US commercial and payer perspective
od: Brian Murray, i wsp.
Wydane: (2023-01-01)

Payer plus pour étudier mieux ?
od: Sandrine Garcia
Wydane: (2008-11-01)

THE TAX ADVANTAGES OF INCOME TAX PAYERS
od: SUCIU GHEORGHE
Wydane: (2015-04-01)

An integrated valuation model for payer and investor
od: Mark Nuijten, i wsp.
Wydane: (2022-12-01)

Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
od: Mabel Aoun, i wsp.
Wydane: (2022-05-01)

Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective
od: Stuart Silverman, i wsp.
Wydane: (2015-01-01)

Incremental cost of premature birth – a public health care payer perspective from Hungary
od: Gábor Kovács, i wsp.
Wydane: (2023-06-01)

The impact of price transparency and competition on hospital costs: a research on all-payer claims databases
od: Ahreum Han, i wsp.
Wydane: (2022-11-01)

Treatment Patterns and Health Care Costs of Lupus Nephritis in a United States Payer Population
od: Bartels-Peculis L, i wsp.
Wydane: (2020-06-01)

Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective
od: Irfan Cicin, i wsp.
Wydane: (2021-06-01)

Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer’s perspective
od: George Joseph, i wsp.
Wydane: (2021-09-01)

Projected costs of single-payer healthcare financing in the United States: A systematic review of economic analyses.
od: Christopher Cai, i wsp.
Wydane: (2020-01-01)

Penal fiscal liability of bailiff as the VAT payer
od: Fabian Nalikowski
Wydane: (2016-03-01)

An Analysis of Psychosis Readmissions: Payer Class Differences
od: Haylei Lorca
Wydane: (2012-01-01)

Correction: Cost of illness of chronic kidney disease in Lebanon: from the societal and third-party payer perspectives
od: Mabel Aoun, i wsp.
Wydane: (2022-06-01)

A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective
od: Baker CL, i wsp.
Wydane: (2018-07-01)

COVID-19-associated costs and mortality in Germany: an incidence-based analysis from a payer’s perspective
od: Florian Brandt, i wsp.
Wydane: (2024-03-01)

Analysis of hospital and payer costs of care: aggressive warming versus routine warming in abdominal major surgery
od: Shujia Song, i wsp.
Wydane: (2023-11-01)

Cost-Effectiveness Of The SQ® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective
od: Vogelberg C, i wsp.
Wydane: (2019-11-01)

MECHANISM OF TAX-PAYER’S LIABILITY IN REALIZATION OF THE BUSINESS GOAL DOCTRINE
od: S. P. Bortnikov
Wydane: (2013-06-01)

INVESTIGATION OF AUTO-ANTIBODIES IN PATIENTS DIAGNOSED WITH FOCAL EPILEPSY
od: Ekizoglu, E, i wsp.
Wydane: (2013)

Estimating the benefits of reduced fracture incidence for patients living with osteogenesis imperfecta and for healthcare payers
od: Edmonds, T, i wsp.
Wydane: (2024)

Challenges of Using NIK as a Tax Payer Identity
od: Titin Fachriah Nur, i wsp.
Wydane: (2022-12-01)

Prescription drug spending by payer: Implications for managed care
od: Yousef Chavehpour, i wsp.
Wydane: (2024-03-01)

COMPETITION AMONG PAYERS IN HEALTH CARE. THEORETICAL APPROACH
od: Anna Hnatyszyn-Dzikowska
Wydane: (2013-06-01)